FDA Chief Eyes Path for Copycat Biotech Drugs

FDA Chief Eyes Path for Copycat Biotech Drugs
Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!